Generic medicines are a key part of Canada’s healthcare system, offering high quality, strong regulatory oversight, and major cost savings. With robust domestic manufacturing and widespread use, generics improve access, support the economy, and strengthen Canada’s healthcare resilience.

Canada’s ability to make its own medicine is under threat. With rising trade tensions and global supply risks, pharmaceutical manufacturing must be treated as a national security priority. This article explores the urgent case for domestic drug production.

This article explores how strengthening Canada’s domestic pharmaceutical manufacturing can protect public health, reduce supply chain risks, and improve equity. As reliance on foreign-made medicines grows, the need for a secure, resilient drug supply has never been more urgent.

Canada must strengthen its pharmaceutical manufacturing sector to secure medicine access, boost economic resilience, and reduce reliance on imports. The CPMEA calls for strategic investment and policy support to help build a sustainable, made-in-Canada production economy.

Discover how Canada’s pharmaceutical manufacturers fuel more than healthcare. From job creation to economic resilience and global trade, their impact is far-reaching—and growing.

Read about how tariffs on medicines threaten Canada’s pharma industry, risking costs, jobs, and North American drug security.

Read about how proposed U.S. tariffs on Canadian medicines threaten national security, raise costs, and disrupt supply.

CPMEA drives growth and innovation in Canada’s pharmaceutical industry, ensuring a resilient future for public health and the economy.

The CPMEA is leading the Canadian pharmaceutical manufacturing sector, advocating for innovative policies, & addressing urgent challenges.

Uncover the valuable role of CPMEA in strengthening Canada's pharmaceutical manufacturing sector.